EcoDrugPlus

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSMOCG00000013182
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMOCG00000002765
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMOCG00000020764
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSMOCG00000015770
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMOCG00000001171
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSMOCG00000009224
Gene Symbol: EPHB4
3 Cross references
166 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMOCG00000010660
Gene Symbol: F2RL3
2 Cross references
196 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSMOCG00000016537
Gene Symbol: FAU
3 Cross references
251 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSMOCG00000015631
Gene Symbol: FKBP1A
3 Cross references
231 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSMOCG00000000559
Gene Symbol: FXYD2
3 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMOCG00000018772
Gene Symbol: FYN
3 Cross references
261 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSMOCG00000002591
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).